Fetal Growth Restriction a Case Control Study

NCT ID: NCT07025031

Last Updated: 2025-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

58 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2027-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to investigate the responsible factors that leads to idiopathic fetal growth restriction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims to investigate the relationship between maternal serum level of progesterone, immune-expression of HMOX-1 a placental angiogenesis marker with idiopathic fetal growth restriction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Fetal Growth Restriction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women with pregnancies affected by idiopathic fetal growth restriction

Women with normal pregnancies and normally growing foetus

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* singleton
* dated pregnancy

Exclusion Criteria

* fetus with structural or chromosomal anomaly
* receive treatments such as aspirin, progestogen, low molecular weight heparin
* has pre-existing medical disorders such as autoimmune disease, hypertension, diabetes
* smoking
* suspected intrauterine infection
Minimum Eligible Age

19 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National University of Malaysia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Canselor Tuanku Muhriz

Kuala Lumpur, Kuala Lumpur, Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rahana Abd Rahman, MOG (UKM)

Role: CONTACT

+60122719985 ext. 5964

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rahana Abd Rahman, MOG (UKM)

Role: primary

+60122719985 ext. 5964

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JEP-2025-183

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.